DCC-2036
DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4 nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively.
Product Specifications
CAS Number
1020172-07-9
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
553.5869
Molecular Formula
C30H28FN7O3
Notes
Research use only, not for human use.
Receptor
Abl1|FLT3|p-Abl1 (native) |p-Abl1 (T315I) |u-Abl1 (native)
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2072769-01 0.1 mL
APC/CY7-Linked Polyclonal Antibody to Glutamate Cysteine Ligase, Catalytic (GCLC)
Ask
View Details MBS2072769-02 0.2 mL
APC/CY7-Linked Polyclonal Antibody to Glutamate Cysteine Ligase, Catalytic (GCLC)
Ask
View Details MBS2072769-03 0.5 mL
APC/CY7-Linked Polyclonal Antibody to Glutamate Cysteine Ligase, Catalytic (GCLC)
Ask
View Details MBS2072769-04 1 mL
APC/CY7-Linked Polyclonal Antibody to Glutamate Cysteine Ligase, Catalytic (GCLC)
Ask
View Details 
MBS2072769-05 5 mL
APC/CY7-Linked Polyclonal Antibody to Glutamate Cysteine Ligase, Catalytic (GCLC)
Ask
View Details